Human Genome reiterated at market outperform

JMP Securities analyst Charles C. Duncan reiterated Human Genome Sciences, Inc. at market outperform in advance of a lupus expert conference call to discuss the data presented at the Annual European League Against Rheumatism meeting in Amsterdam. Based on positive clinical activity and previously reported top-line data, JMP believes Lymphostat-B could be the leading disease-modifying drug in lupus, according to the analyst. Shares of the Rockville, Md.-based biopharmaceutical company were down 17 cents, or 1.71%, at $9.80 on volume of 3,566,620 shares versus the three-month running average of 3,125,420 shares. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.